Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
Show Summaries  |  Hide Summaries
  • Jul. 29, 2011, 12:05 AM
    Notable earnings before Friday's open: ACI, AEP, AGP, AIV, AMGN, AON, AXL, CPN, CVH, CVX, HP, ITT, LPX, MRK, NEM, NWL, PPC, TOT, WY
    | Comment!
  • Jul. 15, 2011, 5:34 PM
    Amgen (AMGN) reaches a settlement with TEVA in its Neupogen patent-infringment lawsuit. The company had filed the claim to block Teva from selling its copycat drug Neutroval, used to prevent infections in patients receiving chemotherapy. Under the agreement, Teva will be prevented from launching Neutroval until 2013. AMGN +1.1%, TEVA -0.1% AH.
    | Comment!
  • Jul. 11, 2011, 9:13 AM
    Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR)
    | Comment!
  • May 17, 2011, 10:53 AM
    Another favorable trial for Amgen's (AMGN) denosumab drug, used in men to treat prostate cancer, as it's seen to delay bone pain in patients. A fall study showed surprisingly good results; analysts expect the drug's annual sales to reach $2.5B by 2015.
    | Comment!
  • Apr. 20, 2011, 4:09 PM
    Amgen (AMGN): Q1 EPS of $1.34 beats by $0.05. Revenue of $3.7B in-line. Shares +0.6% AH. (PR)
    | Comment!
  • Apr. 20, 2011, 12:10 AM
    Notable earnings after Wednesday's close: AAPL, AMGN, AMR, AXP, BSX, CAKE, CMG, CVA, ESV, ETFC, FFIV, GILD, KNX, LRCX, MAR, NE, NFX, PBCT, QCOM, RRR, SLM, TEX, WDC, WLT, YUM
    | Comment!
  • Mar. 24, 2011, 2:25 PM
    Amgen (AMGN +1%) may introduce its first dividend at an April 21 investor meeting, Bloomberg says, boosting a stock whose value has been chopped by a third since 2006. Unlike other biotechs, Amgen can afford to return money to shareholders because it generates a lot of cash compared with capital expenditures. But the projected 2.3% yield would rank well behind drugmakers PFE, MRK and JNJ.
    | 1 Comment
  • Feb. 11, 2011, 2:10 PM
    JPMorgan analysts pick 16 stocks they think will perform well if there's an onset of rapid inflation: NEM, ABX, PFE, TEVA, MRK, CVS, FCX, ABT, APA, AMGN, GILD, WLP, AET, COV, CI, BTU.
    | 1 Comment
  • Feb. 2, 2011, 7:28 AM
    The incredible shrinking blockbuster? Roche (RHHBY.PKreported disappointing full-year earnings and cut its outlook for its key cancer drug Avastin as regulators and doctors reexamine the use of the drug.
    | Comment!
  • Jan. 24, 2011, 4:16 PM
    Amgen (AMGN): Q4 EPS of $1.17 beats by $0.06. Revenue of $3.8B (+1% Y/Y) beats by $35M. Shares +1.1% AH. (PR)
    | Comment!
  • Jan. 24, 2011, 12:10 AM
    Notable earnings after Monday's close: AXP, AMGN, CSX, JEC, SANM, STM, TXN, VMW, ZION
    | Comment!
  • Dec. 31, 2010, 7:51 AM
    The FDA approved around 21 drugs in 2010, a relatively modest figure, with some of the most highly anticipated products delayed into next year or beyond. Among this year's FDA-approval winners: Amgen (AMGN), Roche (RHHBY.PK), Novartis (NVS), Acorda (ACOR) and Dendreon (DNDN).
    | Comment!
  • Dec. 21, 2010, 3:23 PM
    Xoma (XOMA +71%) shares skyrocket after a research report says the company’s once-a-month diabetes drug could lead a potential blockbuster class of drugs. Xoma's IL-1 inhibitor could give it an edge among competitors including Novartis (NVS), Amgen (AMGN) and Eli Lilly (LLY), according to Sumner Street Research.
    | 2 Comments
  • Dec. 14, 2010, 9:00 AM
    Premarket gainers: GXDX +17%. AMGN +4%. BP +4%.
    Losers: LCI -13%. BBY -13%. LPH -12%. ICO -11%. LXRX -10%. YMI -8%. AHT -6%. OXPS -5%. VECO -5%. REE -5%. WPZ -4%.
    | Comment!
  • Dec. 14, 2010, 8:10 AM
    Shares of Amgen (AMGN) are +6.7% premarket after the company's disclosure yesterday evening that its bone drug denosumab delayed the spread of prostate cancer to bones in a clinical trial. Analysts had expected a less favorable trial result.
    | Comment!
  • Oct. 26, 2010, 7:52 AM
    Savient's (SVNT +4.4%) 44% drop yesterday may have been just what suitors were waiting for. With shares now trading near $12, potential bidders (like ABT, PFE, AMGN) might come back to the table and fair value may turn out to be closer to $20/share than the $47/share target some analysts had previously suggested.
    | Comment!
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States